Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Cervical Cancer, January 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 225 articles:
HTML format


 

Single Articles

  1. AL-HAMMADI FA, Al-Tahri F, Al-Ali A, Nair SC, et al
    Limited Understanding of Pap Smear Testing among Women, a Barrier to Cervical Cancer Screening in the United Arab Emirates
    Asian Pac J Cancer Prev. 2017;18:3379-3387.
    Abstract    

    Abstract available

  2. HAUGE A, Wegner CS, Gaustad JV, Simonsen TG, et al
    Diffusion-weighted MRI-derived ADC values reflect collagen I content in PDX models of uterine cervical cancer.
    Oncotarget. 2017;8:105682-105691.
    Abstract    

    Abstract available

  3. JIN Y, Kim SC, Kim HJ, Ju W, et al
    Use of autoantibodies against tumor-associated antigens as serum biomarkers for primary screening of cervical cancer.
    Oncotarget. 2017;8:105425-105439.
    Abstract    

    Abstract available

  4. VATTAI A, Cavailles V, Sixou S, Beyer S, et al
    Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer.
    Oncotarget. 2017;8:105356-105371.
    Abstract    

    Abstract available

  5. SEN P, Ganguly P, Ganguly N
    Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer.
    Oncol Lett. 2018;15:11-22.
    Abstract    

    Abstract available

  6. ZHAI L, Li Y, Lan X, Ai L, et al
    MicroRNA-10a-5p suppresses cancer proliferation and division in human cervical cancer by targeting BDNF.
    Exp Ther Med. 2017;14:6147-6151.
    Abstract    

    Abstract available

  7. GONG P, Hu C, Zhou X, Wang R, et al
    TAT-mediated si-hWAPL inhibits the invasion and metastasis of cervical cancer stem cells.
    Exp Ther Med. 2017;14:5452-5458.
    Abstract    

    Abstract available

  8. WEI Y, Dong J, Li F, Wei Z, et al
    Knockdown of SLC39A7 suppresses cell proliferation, migration and invasion in cervical cancer.
    EXCLI J. 2017;16:1165-1176.
    Abstract    

    Abstract available

  9. MAZDZIARZ A, Wygledowski J, Osuch B, Jagielska B, et al
    New directions in cervical cancer prophylaxis worldwide and in Poland - Case study of the Polish rural female population.
    Ann Agric Environ Med. 2017;24:592-595.
    Abstract    

    Abstract available

  10. BECERRA-CULQUI TA, Lonky NM, Chen Q, Chao CR, et al
    Patterns and correlates of cervical cancer screening initiation in a large integrated healthcare system.
    Am J Obstet Gynecol. 2017 Dec 22. pii: S0002-9378(17)32708.
    Abstract    

    Abstract available

  11. ERKU DA, Netere AK, Mersha AG, Abebe SA, et al
    Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia.
    Gynecol Oncol Res Pract. 2017;4:20.
    Abstract    

    Abstract available

  12. UMEZAWA R, Murakami N, Nakamura S, Wakita A, et al
    Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: A single-institution study.
    Brachytherapy. 2017 Dec 21. pii: S1538-4721(17)30532.
    Abstract    

    Abstract available

  13. CIHORIC N, Tsikkinis A, Vlaskou Badra E, Glatzer M, et al
    Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
    Radiat Oncol. 2017;12:202.
    Abstract    

    Abstract available

  14. EHRENPREIS ED, Smith DG
    Patients with newly diagnosed cervical cancer should be screened for anal human papilloma virus and anal dysplasia: Results of a pilot study using a STELLA computer simulation and economic model.
    Papillomavirus Res. 2017;5:38-45.
    Abstract    

    Abstract available

  15. YE GL, Du DL, Jin LJ, Wang LL, et al
    Sensitization of TRAIL-resistant cervical cancer cells through combination of TRAIL and fucoxanthin treatments.
    Eur Rev Med Pharmacol Sci. 2017;21:5594-5601.
    Abstract    

    Abstract available

  16. WEI H, Zhang JJ, Tang QL
    MiR-638 inhibits cervical cancer metastasis through Wnt/beta-catenin signaling pathway and correlates with prognosis of cervical cancer patients.
    Eur Rev Med Pharmacol Sci. 2017;21:5587-5593.
    Abstract    

    Abstract available

  17. ZHAO Y, Liu X, Lu YX
    MicroRNA-143 regulates the proliferation and apoptosis of cervical cancer cells by targeting HIF-1alpha.
    Eur Rev Med Pharmacol Sci. 2017;21:5580-5586.
    Abstract    

    Abstract available

  18. TEOH D, Shaikh R, Vogel RI, Zoellner T, et al
    A Cross-Sectional Review of Cervical Cancer Messages on Twitter During Cervical Cancer Awareness Month.
    J Low Genit Tract Dis. 2018;22:8-12.
    Abstract    

    Abstract available

  19. HAMMER A, Hee L, Blaakaer J, Gravitt P, et al
    Temporal Patterns of Cervical Cancer Screening Among Danish Women 55 Years and Older Diagnosed With Cervical Cancer.
    J Low Genit Tract Dis. 2018;22:1-7.
    Abstract    

    Abstract available

  20. ASHRAFI-ASGARABAD A, Safiri S
    Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy: methodological issues.
    Arch Gynecol Obstet. 2017 Dec 21. pii: 10.1007/s00404-017-4629.
    Abstract    



  21. WU SG, Zhang WW, He ZY, Sun JY, et al
    Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer.
    Cancer Manag Res. 2017;9:813-819.
    Abstract    

    Abstract available

  22. ZHEN S, Li X
    Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
    Cell Physiol Biochem. 2017;44:2455-2466.
    Abstract    

    Abstract available

  23. RAFAEL RMR, Moura ATMS
    Severe intimate partner physical violence as a risk factor for inadequate cervical cancer screening.
    Cad Saude Publica. 2017;33:e00074216.
    Abstract    

    Abstract available

  24. WU MH, Lin CL, Chiou HL, Yang SF, et al
    Praeruptorin A Inhibits Human Cervical Cancer Cell Growth and Invasion by Suppressing MMP-2 Expression and ERK1/2 Signaling.
    Int J Mol Sci. 2017;19.
    Abstract    

    Abstract available

  25. YANG X, Cheng Y, Li C
    The role of TLRs in cervical cancer with HPV infection: a review.
    Signal Transduct Target Ther. 2017;2:17055.
    Abstract    

    Abstract available

  26. OH J, Seol KH, Lee HJ, Choi YS, et al
    Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer.
    Radiat Oncol J. 2017 Dec 23. pii: roj.2017.00367. doi: 10.3857/roj.2017.00367.
    Abstract    

    Abstract available

  27. WANG W, Meng Q, Hou X, Lian X, et al
    Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer.
    Oncotarget. 2017;8:102965-102973.
    Abstract    

    Abstract available

  28. WASIM L, Chopra M
    Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
    Cell Oncol (Dordr). 2017 Dec 19. pii: 10.1007/s13402-017-0366.
    Abstract    

    Abstract available

  29. VAJDA R, Arvane Egri C, Kovacs A, Budai A, et al
    [Quality and performance indicators of the pilot program for cervical cancer screening by health visitors].
    Magy Onkol. 2017;61:361-367.
    Abstract    

    Abstract available

  30. ILIYASU AM, Fatichah C
    A Quantum Hybrid PSO Combined with Fuzzy k-NN Approach to Feature Selection and Cell Classification in Cervical Cancer Detection.
    Sensors (Basel). 2017;17.
    Abstract    

    Abstract available

  31. WANG D, Li Q, Li Y, Wang H, et al
    The role of MCM5 expression in cervical cancer: Correlation with progression and prognosis.
    Biomed Pharmacother. 2017;98:165-172.
    Abstract    

    Abstract available

  32. KANGMENNAANG J, Onyango EO, Luginaah I, Elliott SJ, et al
    The next Sub Saharan African epidemic? A case study of the determinants of cervical cancer knowledge and screening in Kenya.
    Soc Sci Med. 2017;197:203-212.
    Abstract    

    Abstract available

  33. RONCO G, Baussano I
    Causal system modelling of cervical cancer screening.
    Lancet Public Health. 2017;2:e61-e62.
    Abstract    



  34. GUIDO R
    Cervical Cancer Screening.
    Clin Obstet Gynecol. 2017 Dec 15. doi: 10.1097/GRF.0000000000000336.
    Abstract    

    Abstract available

  35. ZHOU WJ, Yang HL, Chang KK, Meng Y, et al
    Human thymic stromal lymphopoietin promotes the proliferation and invasion of cervical cancer cells by downregulating microRNA-132 expression.
    Oncol Lett. 2017;14:7910-7916.
    Abstract    

    Abstract available

  36. BOU-ORM IR, Sakr RE, Adib SM
    Cervical cancer screening among Lebanese women.
    Rev Epidemiol Sante Publique. 2017 Dec 14. pii: S0398-7620(17)30526.
    Abstract    

    Abstract available

  37. GUO F, Chen YZ, Li L, Chen C, et al
    Long non-coding RNA XLOC_008466 acts as an oncogenic molecular in cervical cancer tumorigenesis.
    Biomed Pharmacother. 2017;98:88-94.
    Abstract    

    Abstract available

  38. CASTANON A, Sasieni P
    Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern?
    Prev Med. 2017;107:21-28.
    Abstract    

    Abstract available

  39. REN CC, Yang L, Liu L, Chen YN, et al
    Effects of shRNA-mediated Silencing of PSMA7 on Cell Proliferation and Vascular Endothelial Growth Factor Expression via the Ubiquitin-Proteasome Pathway in Cervical Cancer.
    J Cell Physiol. 2017 Dec 16. doi: 10.1002/jcp.26408.
    Abstract    

    Abstract available

  40. LIU J, Ni S
    Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma.
    Gene. 2018;642:256-260.
    Abstract    

    Abstract available

  41. LYTVYNENKO M, Bocharova T, Zhelezniakova N, Narbutova T, et al
    CERVICAL TRANSFORMATION IN ALCOHOL ABUSE PATIENTS.
    Georgian Med News. 2017;:12-17.
    Abstract    

    Abstract available

  42. KRUAKAEW S, Seeka C, Lhinhatrakool T, Thongnest S, et al
    Cytotoxic Cardiac Glycoside Constituents of Vallaris glabra Leaves.
    J Nat Prod. 2017;80:2987-2996.
    Abstract    

    Abstract available

  43. DROLET M, Laprise JF, Brotherton JML, Donovan B, et al
    The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation.
    J Infect Dis. 2017 Sep 12. doi: 10.1093.
    Abstract    

    Abstract available

  44. GRAVITT PE, Winer RL
    Natural History of HPV Infection across the Lifespan: Role of Viral Latency.
    Viruses. 2017;9.
    Abstract    

    Abstract available

  45. TROPE A, Engesaeter B, Nygard M, Andreassen T, et al

    Tidsskr Nor Laegeforen. 2017;137.
    Abstract    



  46. LIU M, An J, Huang M, Wang L, et al
    MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas.
    Mol Carcinog. 2018;57:32-43.
    Abstract    

    Abstract available

  47. BURTON ER, Sorosky JI
    Recognition and Therapeutic Options for Malignancy of the Cervix and Uterus.
    Obstet Gynecol Clin North Am. 2017;44:195-206.
    Abstract    

    Abstract available

  48. SUN Y, Peng S, Yang A, Farmer E, et al
    Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.
    Gene Ther. 2017;24:408-415.
    Abstract    

    Abstract available

  49. GANTA V, Moonie S, Patel D, Hunt AT, et al
    Timely reminder interventions to improve annual Papanicolaou (Pap) smear rates among HIV-infected women in an outpatient center of southern Nevada: a short report.
    AIDS Care. 2017;29:1099-1101.
    Abstract    

    Abstract available

  50. JACOB D, Lamberto M, DeSouza Lawrence L, Mourtada F, et al
    Clinical transition to model-based dose calculation algorithm: A retrospective analysis of high-dose-rate tandem and ring brachytherapy of the cervix.
    Brachytherapy. 2017;16:624-629.
    Abstract    

    Abstract available

  51. EID W, Abdel-Rehim W
    Neferine Enhances the Antitumor Effect of Mitomycin-C in Hela Cells Through the Activation of p38-MAPK Pathway.
    J Cell Biochem. 2017;118:3472-3479.
    Abstract    

    Abstract available

  52. PIZZO K, Arnold C, Wispelwey B
    Actinomyces neuii Causing Vertebral Osteomyelitis.
    Am J Med Sci. 2017;353:407-410.
    Abstract    



  53. ZHOU J, Wu SG, Sun JY, Li FY, et al
    The effect of local treatment modalities in patients with early-stage adenocarcinoma of the uterine cervix: A population-based analysis.
    Int J Surg. 2017;41:16-22.
    Abstract    

    Abstract available

  54. GOTTVALL M, Stenhammar C, Grandahl M
    Parents' views of including young boys in the Swedish national school-based HPV vaccination programme: a qualitative study.
    BMJ Open. 2017;7:e014255.
    Abstract    

    Abstract available

  55. FILHO SMA, Bertoni N, Brant AC, Vidal JPCB, et al
    Methylation at 3'LCR of HPV16 can be affected by patient age and disruption of E1 or E2 genes.
    Virus Res. 2017;232:48-53.
    Abstract    

    Abstract available

  56. THAKER PH, Salani R, Brady WE, Lankes HA, et al
    A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
    Ann Oncol. 2017;28:505-511.
    Abstract    

    Abstract available

  57. ZHANG Y, Jin LP
    Effects of TSLP on obstetrical and gynecological diseases.
    Am J Reprod Immunol. 2017;77.
    Abstract    

    Abstract available

  58. CHRISTENSEN ND, Budgeon LR, Cladel NM, Hu J, et al
    Recent advances in preclinical model systems for papillomaviruses.
    Virus Res. 2017;231:108-118.
    Abstract    

    Abstract available

  59. YANG A, Farmer E, Lin J, Wu TC, et al
    The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
    Virus Res. 2016 Dec 5. pii: S0168-1702(16)30556.
    Abstract    

    Abstract available

  60. SCHELLENBACHER C, Roden RB, Kirnbauer R
    Developments in L2-based Human Papillomavirus (HPV) Vaccines.
    Virus Res. 2016 Nov 23. pii: S0168-1702(16)30528.
    Abstract    

    Abstract available

  61. SONG Y, Tan EL, Jiang X, Cheng JZ, et al
    Accurate Cervical Cell Segmentation from Overlapping Clumps in Pap Smear Images.
    IEEE Trans Med Imaging. 2017;36:288-300.
    Abstract    

    Abstract available

  62. FIELDING S, Rothnie K, Gray NM, Little J, et al
    Psychosocial morbidity in women with abnormal cervical cytology managed by cytological surveillance or initial colposcopy: longitudinal analysis from the TOMBOLA randomised trial.
    Psychooncology. 2017;26:476-483.
    Abstract    

    Abstract available

  63. CHORLEY AJ, Marlow LA, Forster AS, Haddrell JB, et al
    Experiences of cervical screening and barriers to participation in the context of an organised programme: a systematic review and thematic synthesis.
    Psychooncology. 2017;26:161-172.
    Abstract    

    Abstract available

  64. EL SAYED ME, Bahadur YA, Hassouna AH, Fawzy EE, et al
    Outcome of cervix uteri cancer patients: Clinical treatment results and toxicity profile in a retrospective study from Saudi Arabia.
    Asia Pac J Clin Oncol. 2017;13:e364-e372.
    Abstract    

    Abstract available

  65. SLAMA J
    [Current limits of cervical cancer prevention in the Czech republic].
    Ceska Gynekol. 2017;82:482-486.
    Abstract    

    Abstract available

  66. XIE X, Song K, Cui B, Jiang J, et al
    A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.
    Int J Clin Oncol. 2018 Jan 3. pii: 10.1007/s10147-017-1225.
    Abstract    

    Abstract available

  67. ZHU X, Zhou L, Li R, Shen Q, et al
    AGER promotes proliferation and migration in cervical cancer.
    Biosci Rep. 2018 Jan 3. pii: BSR20171329. doi: 10.1042/BSR20171329.
    Abstract    

    Abstract available

  68. PLISSONNIER ML, Fauconnet S, Bittard H, Mougin C, et al
    Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.
    Oncotarget. 2017;8:107744-107762.
    Abstract    

    Abstract available

  69. WANG Y, Tian Y
    miR-206 inhibits cell proliferation, migration, and invasion by targeting BAG3 in human cervical cancer.
    Oncol Res. 2018 Jan 2. doi: 10.3727/096504017X15143731031009.
    Abstract    

    Abstract available

  70. SHI X, Yuan N, Zhang S, Yuan F, et al
    MicroRNA-379 suppresses cervical cancer cell proliferation and invasion by directly targeting V-crk avian sarcoma virus CT10 oncogene homolog-like.
    Oncol Res. 2018 Jan 2. doi: 10.3727/096504017X15140534417184.
    Abstract    

    Abstract available

  71. NGWENYA D, Huang SL
    Knowledge, attitude and practice on cervical cancer and screening: a survey of men and women in Swaziland.
    J Public Health (Oxf). 2017 Dec 27. pii: 4779874. doi: 10.1093.
    Abstract    

    Abstract available

  72. GULER OC, Torun N, Yyldyrym BA, Onal C, et al
    Pretreatment metabolic tumor volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
    Br J Radiol. 2018 Jan 2:20170552. doi: 10.1259/bjr.20170552.
    Abstract    

    Abstract available

  73. CHEN JW, Chen HB, He Q, Liao YL, et al
    [Rectal toxicity prediction based on accurate rectal surface dose summation for cervical cancer radiotherapy].
    Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:1626-1631.
    Abstract    

    Abstract available

  74. JIN Y, Qiu S, Shao N, Zheng J, et al
    Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-kappaB Signaling Pathway.
    Med Sci Monit. 2018;24:11-18.
    Abstract    

    Abstract available

  75. MEI Y, Peng C, Liu YB, Wang J, et al
    Silencing RIF1 decreases cell growth, migration and increases cisplatin sensitivity of human cervical cancer cells.
    Oncotarget. 2017;8:107044-107051.
    Abstract    

    Abstract available

  76. MATSUO K, Shimada M, Yokota H, Satoh T, et al
    Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.
    Oncotarget. 2017;8:106866-106875.
    Abstract    

    Abstract available

  77. EO WK, Kwon BS, Kim KH, Kim HY, et al
    Monocytosis as a prognostic factor for survival in stage IB and IIA cervical cancer.
    J Cancer. 2018;9:64-70.
    Abstract    

    Abstract available

  78. YIM GW, Eoh KJ, Chung YS, Kim SW, et al
    Perioperative Outcomes of 3-Arm Versus 4-Arm Robotic Radical Hysterectomy in Patients with Cervical Cancer.
    J Minim Invasive Gynecol. 2017 Dec 26. pii: S1553-4650(17)31338.
    Abstract    

    Abstract available

  79. SKORZYNSKA H, Krawczyk-Suszek M, Kulik TB, Pacian A, et al
    Attitudes of women after the age of 50 towards preventive screening.
    Ann Agric Environ Med. 2017;24:624-627.
    Abstract    

    Abstract available

  80. OKONOGI N, Wakatsuki M, Kato S, Shiba S, et al
    Long-term Outcomes of Carbon-ion Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:457-463.
    Abstract    

    Abstract available

  81. KYRGIOU M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, et al
    Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.
    Cochrane Database Syst Rev. 2017;11:CD012847.
    Abstract    

    Abstract available

  82. MOSES A, Mwafongo A, Chikasema M, Kafantenganji L, et al
    Risk factors for common cancers among patients at Kamuzu Central Hospital in Lilongwe, Malawi: A retrospective cohort study.
    Malawi Med J. 2017;29:136-141.
    Abstract    

    Abstract available

  83. LEE HJ, Lee JJ, Park JY, Kim JH, et al
    Prognostic value of metabolic parameters determined by preoperative (1)(8)F-FDG PET/CT in patients with uterine carcinosarcoma.
    J Gynecol Oncol. 2017;28:e43.
    Abstract    

    Abstract available

  84. PRETI M, Bucchi L, Ghiringhello B, Privitera S, et al
    Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy.
    J Gynecol Oncol. 2017;28:e27.
    Abstract    

    Abstract available

  85. CREMER M, Paul P, Bergman K, Haas M, et al
    A Non-Gas-Based Cryotherapy System for the Treatment of Cervical Intraepithelial Neoplasia: A Mixed-Methods Approach for Initial Development and Testing.
    Glob Health Sci Pract. 2017;5:57-64.
    Abstract    

    Abstract available

  86. PENG J, Wang W, Zeng D
    Application of magnetic resonance imaging in diagnosis of Uterus Cervical Carcinoma.
    J Xray Sci Technol. 2017;25:205-211.
    Abstract    

    Abstract available

  87. SHAW W, Rae WID, Alber ML
    Image-guided adaptive brachytherapy dose escalation for cervix cancer via fractionation compensation.
    Brachytherapy. 2017;16:534-546.
    Abstract    

    Abstract available

  88. LAI D, Bodson J, Davis FA, Lee D, et al
    Diverse Families' Experiences with HPV Vaccine Information Sources: A Community-Based Participatory Approach.
    J Community Health. 2017;42:400-412.
    Abstract    

    Abstract available

  89. MATTINGLY M, Juran R, Su I, Ebinger J, et al
    Patient knowledge of hysterectomy and pap screening after minimally invasive hysterectomy.
    Patient Educ Couns. 2017;100:121-125.
    Abstract    

    Abstract available

  90. KELLY PJ, Hunter J, Daily EB, Ramaswamy M, et al
    Challenges to Pap Smear Follow-up among Women in the Criminal Justice System.
    J Community Health. 2017;42:15-20.
    Abstract    

    Abstract available

  91. DUAN C, Kallehauge JF, Bretthorst GL, Tanderup K, et al
    Are complex DCE-MRI models supported by clinical data?
    Magn Reson Med. 2017;77:1329-1339.
    Abstract    

    Abstract available

  92. WANG X, Jiang Z, An J, Mao X, et al
    Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
    Mol Med Rep. 2018 Jan 9. doi: 10.3892/mmr.2018.8414.
    Abstract    

    Abstract available

  93. WANG L, Chai L, Ji Q, Cheng R, et al
    Forkhead box protein C1 promotes cell proliferation and invasion in human cervical cancer.
    Mol Med Rep. 2018 Jan 11. doi: 10.3892/mmr.2018.8423.
    Abstract    

    Abstract available

  94. WANG LN, Wang F, Liu J, Jin YH, et al
    CYP1A1 Ile462Val Polymorphism Is Associated with Cervical Cancer Risk in Caucasians Not Asians: A Meta-Analysis.
    Front Physiol. 2017;8:1081.
    Abstract    

    Abstract available

  95. HUI BB, Reulein CP, Guy RJ, Donovan B, et al
    Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of Trichomonas vaginalis: a modelling study.
    Sex Transm Infect. 2018 Jan 11. pii: sextrans-2017-053294.
    Abstract    

    Abstract available

  96. ISLAM JY, Khatun F, Alam A, Sultana F, et al
    Knowledge of cervical cancer and HPV vaccine in Bangladeshi women: a population based, cross-sectional study.
    BMC Womens Health. 2018;18:15.
    Abstract    

    Abstract available

  97. JASSIM G, Obeid A, Al Nasheet HA
    Knowledge, attitudes, and practices regarding cervical cancer and screening among women visiting primary health care Centres in Bahrain.
    BMC Public Health. 2018;18:128.
    Abstract    

    Abstract available

  98. CHOI Y, Ahn KJ, Park SK, Cho H, et al
    Correction: Adverse effect of excess body weight on survival in cervical cancer patients after surgery and radiotherapy.
    Radiat Oncol J. 2017;35:385.
    Abstract    

    Abstract available

  99. OLOLADE K, Mokgoro NP, Lawal IO, Vorster M, et al
    A comparison of (18)F-FDG PET/CT findings in HIV positive compared to HIV negative patients with recurrent cervical cancer.
    Hell J Nucl Med. 2017;20 Suppl:71-79.
    Abstract    

    Abstract available

  100. JIANG L, Shi S, Shi Q, Zhang H, et al
    MicroRNA-519d-3p inhibits proliferation and promotes apoptosis by targeting HIF-2alpha in cervical cancer under hypoxic conditions.
    Oncol Res. 2018 Jan 10. doi: 10.3727/096504018X15152056890500.
    Abstract    

    Abstract available

  101. SAETERDAL I, Juvet LK, Natvig Norderhaug I, Liu Q, et al
    The overexpression of PXN promotes tumor progression and leads to radioresistance in cervical cancer.
    Future Oncol. 2018 Jan 10. doi: 10.2217/fon-2017-0474.
    Abstract    

    Abstract available

  102. VALENTINI AL, Micco M, Gui B, Giuliani M, et al
    The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.
    Eur Radiol. 2018 Jan 9. pii: 10.1007/s00330-017-5233.
    Abstract    

    Abstract available

  103. TAX C, Abbink K, Rovers MM, Bekkers RLM, et al
    Para-aortic lymphadenectomy in advanced stage cervical cancer, a protocol for comparing safety, feasibility and diagnostic accuracy of surgical staging versus PET-CT; PALDISC trial.
    Pilot Feasibility Stud. 2018;4:27.
    Abstract    

    Abstract available

  104. MINAMI H, Nagasaki T, Akiyoshi T, Konishi T, et al
    Laparoscopic repair of bowel herniation into the space between the obturator nerve and the umbilical artery after pelvic lymphadenectomy for cervical cancer.
    Asian J Endosc Surg. 2018 Jan 4. doi: 10.1111/ases.12458.
    Abstract    

    Abstract available

  105. LI L, Sun JX, Wang XQ, Liu XK, et al
    Notoginsenoside R7 suppresses cervical cancer via PI3K/PTEN/Akt/mTOR signaling.
    Oncotarget. 2017;8:109487-109496.
    Abstract    

    Abstract available

  106. LONG NP, Jung KH, Yoon SJ, Anh NH, et al
    Systematic assessment of cervical cancer initiation and progression uncovers genetic panels for deep learning-based early diagnosis and proposes novel diagnostic and prognostic biomarkers.
    Oncotarget. 2017;8:109436-109456.
    Abstract    

    Abstract available

  107. SEABRA MAL, Candido EB, Vidigal PVT, Lamaita RM, et al
    Immunohistochemical WWOX Expression and Association with Angiogenesis, p53 Expression, Cell Proliferation and Clinicopathological Parameters in Cervical Cancer.
    Rev Bras Ginecol Obstet. 2018 Jan 8. doi: 10.1055/s-0037-1618597.
    Abstract    

    Abstract available

  108. NGUYEN-TRUONG CKY, Hassouneh D, Lee-Lin F, Hsiao CY, et al
    Health Care Providers' Perspectives on Barriers and Facilitators to Cervical Cancer Screening in Vietnamese American Women.
    J Transcult Nurs. 2017 Dec 1:1043659617745135. doi: 10.1177/1043659617745135.
    Abstract    

    Abstract available

  109. YANG Y, Liu Y, Li G, Li L, et al
    Vaginal Stump Ligation for Cervical Cancer.
    Iran J Public Health. 2017;46:1332-1337.
    Abstract    

    Abstract available

  110. LI H, Duan D, Xu J, Gong Q, et al
    The Incidence and Mortality of Cervical Cancer in Ningbo during 2006-2014, China.
    Iran J Public Health. 2017;46:1324-1331.
    Abstract    

    Abstract available

  111. GINSBURG O, Paskett ED
    Ethnic and racial disparities in cervical cancer: lessons from a modelling study of cervical cancer prevention.
    Lancet Public Health. 2018;3:e8-e9.
    Abstract    



  112. WENTZENSEN N, Schiffman M
    Accelerating cervical cancer control and prevention.
    Lancet Public Health. 2018;3:e6-e7.
    Abstract    



  113. JOHNSON HC, Lafferty EI, Eggo RM, Louie K, et al
    Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study.
    Lancet Public Health. 2018;3:e44-e51.
    Abstract    

    Abstract available

  114. CASTANON A, Landy R, Pesola F, Windridge P, et al
    Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
    Lancet Public Health. 2018;3:e34-e43.
    Abstract    

    Abstract available

  115. DISIS MLN
    Movie Review of The Immortal Life of Henrietta Lacks.
    JAMA. 2017;318:2410-2412.
    Abstract    



  116. LIU L, Chen LM, Tao X, Dai F, et al
    [Clinical outcome and high risk factor for residual lesion analysis of HSIL half a year after loop electrosurgical excision procedure: a clinical study of 1 502 cases].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:751-756.
    Abstract    

    Abstract available

  117. HE Y, Wu YM, Yin CH, Geng YN, et al
    [Natural changes of high-risk HPV in women with negative for intraepithelial lesion or malignancy: a prospective 1 year study].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:740-744.
    Abstract    

    Abstract available

  118. WU Y, Zhao J, Hu J, Wu XW, et al
    [Significance of p16/Ki-67 double immunocytochemical staining in cervical cytology ASCUS, LSIL, and ASC-H].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:734-739.
    Abstract    

    Abstract available

  119. NASIOUDIS D, Alevizakos M, Chapman-Davis E, Witkin SS, et al
    Rhabdomyosarcoma of the lower female genital tract: an analysis of 144 cases.
    Arch Gynecol Obstet. 2017;296:327-334.
    Abstract    

    Abstract available

  120. ORTEGA O, Ondo-Mendez A, Garzon R
    [STAT3 activation by hypoxia in in vitro models of cervix cancer and endothelial cells].
    Biomedica. 2017;37:119-130.
    Abstract    

    Abstract available

  121. LIN J, Chen L, Qiu X, Zhang N, et al
    Traditional Chinese medicine for human papillomavirus (HPV) infections: A systematic review.
    Biosci Trends. 2017;11:267-273.
    Abstract    

    Abstract available

  122. VARAN C, Wickstrom H, Sandler N, Aktas Y, et al
    Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration.
    Int J Pharm. 2017;531:701-713.
    Abstract    

    Abstract available

  123. MACH CM, Kha C, Nguyen D, Shumway J, et al
    A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    J Clin Pharm Ther. 2017;42:286-291.
    Abstract    

    Abstract available

  124. CHANDRA J, Dutton JL, Li B, Woo WP, et al
    DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.
    J Immunother. 2017;40:62-70.
    Abstract    

    Abstract available

  125. RAGONNAUD E, Andersson AC, Mariya S, Pedersen AG, et al
    Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix.
    J Immunother. 2017;40:51-61.
    Abstract    

    Abstract available

  126. ZIEMKE P, Griesser H
    [Indications for p16/Ki-67 in cervical cytology].
    Pathologe. 2017;38:38-44.
    Abstract    

    Abstract available

  127. LIN M, Yu X, Chen Y, Ouyang H, et al
    Contribution of mono-exponential, bi-exponential and stretched exponential model-based diffusion-weighted MR imaging in the diagnosis and differentiation of uterine cervical carcinoma.
    Eur Radiol. 2017;27:2400-2410.
    Abstract    

    Abstract available

  128. GELOVER E, Katherine C, Mart C, Sun W, et al
    Patient's specific integration of OAR doses (D2 cc) from EBRT and 3D image-guided brachytherapy for cervical cancer.
    J Appl Clin Med Phys. 2018 Jan 19. doi: 10.1002/acm2.12247.
    Abstract    

    Abstract available

  129. KHANAM R, Kumar R, Hejazi II, Shahabuddin S, et al
    Piperazine clubbed with 2-azetidinone derivatives suppresses proliferation, migration and induces apoptosis in human cervical cancer HeLa cells through oxidative stress mediated intrinsic mitochondrial pathway.
    Apoptosis. 2018 Jan 18. pii: 10.1007/s10495-018-1439.
    Abstract    

    Abstract available

  130. HATA M, Koike I, Miyagi E, Numazaki R, et al
    Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas.
    Oncotarget. 2017;8:112855-112866.
    Abstract    

    Abstract available

  131. BASU BAUL TS, Longkumer I, Duthie A, Singh P, et al
    Triphenylstannyl((arylimino)methyl)benzoates with selective potency that induce G1 and G2/M cell cycle arrest and trigger apoptosis via ROS in human cervical cancer cells.
    Dalton Trans. 2018 Jan 18. doi: 10.1039/c7dt04037.
    Abstract    

    Abstract available

  132. YUAN Y, Ye HQ, Ren QC
    Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer.
    Int J Oncol. 2018;52:461-472.
    Abstract    

    Abstract available

  133. SATO N, Saga Y, Uchibori R, Tsukahara T, et al
    Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4245.
    Abstract    

    Abstract available

  134. CHEN HH, Chen SP, Zheng QL, Nie SP, et al
    Genistein Promotes Proliferation of Human Cervical Cancer Cells Through Estrogen Receptor-Mediated PI3K/Akt-NF-kappaB Pathway.
    J Cancer. 2018;9:288-295.
    Abstract    

    Abstract available

  135. ZHANG B, Wei CY, Chang KK, Yu JJ, et al
    TSLP promotes angiogenesis of human umbilical vein endothelial cells by strengthening the crosstalk between cervical cancer cells and eosinophils.
    Oncol Lett. 2017;14:7483-7488.
    Abstract    

    Abstract available

  136. ZHAO J, Li B, Shu C, Ma Y, et al
    Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.
    Oncol Lett. 2017;14:7437-7442.
    Abstract    

    Abstract available

  137. ZHANG Y, Zhu W, Zhang X, Qu Q, et al
    Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer.
    Oncol Lett. 2017;14:7225-7231.
    Abstract    

    Abstract available

  138. OUYANG Y, Wang Y, Chen K, Cao X, et al
    Clinical outcome of extended-field irradiation vs. pelvic irradiation using intensity-modulated radiotherapy for cervical cancer.
    Oncol Lett. 2017;14:7069-7076.
    Abstract    

    Abstract available

  139. POUDYAL D, Herman A, Adelsberger JW, Yang J, et al
    A novel microRNA, hsa-miR-6852 differentially regulated by Interleukin-27 induces necrosis in cervical cancer cells by downregulating the FoxM1 expression.
    Sci Rep. 2018;8:900.
    Abstract    

    Abstract available

  140. ABULIZI G, Abulimiti T, Li H, Abuduxikuer G, et al
    Knowledge of cervical cancer and Pap smear among Uyghur women from Xinjiang, China.
    BMC Womens Health. 2018;18:21.
    Abstract    

    Abstract available

  141. LUO Q, Luo L, Tang L
    A Network Meta-Analysis on the Diagnostic Value of Different Imaging Methods for Lymph Node Metastases in Patients With Cervical Cancer.
    Technol Cancer Res Treat. 2018;17:1533034617742311.
    Abstract    

    Abstract available

  142. GONZALEZ ZM
    [Screening program for cervical cancer: public policies and experiences of actors who implement the program in the state of Veracruz, Mexico].
    Salud Colect. 2017;13:521-535.
    Abstract    

    Abstract available

  143. NDIZEYE Z, Vanden Broeck D, Vermandere H, Bogers JP, et al
    Knowledge and practices of general practitioners at district hospitals towards cervical cancer prevention in Burundi, 2015: a cross-sectional study.
    Global Health. 2018;14:4.
    Abstract    

    Abstract available

  144. BABAZADEH T, Nadrian H, Moghaddam HR, Ezzati E, et al
    Cognitive determinants of cervical cancer screening behavior amongst housewife women in Iran: an application of Health Belief Model.
    Health Care Women Int. 2018 Jan 17:0. doi: 10.1080/07399332.2018.1425873.
    Abstract    

    Abstract available

  145. LIU M, Jia J, Wang X, Liu Y, et al
    Long non-coding RNA HOTAIR promotes cervical cancer progression through regulating BCL2 via targeting miR-143-3p.
    Cancer Biol Ther. 2018 Jan 16:0. doi: 10.1080/15384047.2018.1423921.
    Abstract    

    Abstract available

  146. LI Q, Feng Y, Chao X, Shi S, et al
    HOTAIR contributes to cell proliferation and metastasis of cervical cancer via targeting miR-23b/MAPK1 axis.
    Biosci Rep. 2018 Jan 15. pii: BSR20171563. doi: 10.1042/BSR20171563.
    Abstract    

    Abstract available

  147. WILLIAMS MS, Kenu E, Dzubey I, Dennis-Antwi JA, et al
    A qualitative study of cervical cancer and cervical cancer screening awareness among Nurses in Ghana.
    Health Care Women Int. 2018 Jan 15:0. doi: 10.1080/07399332.2018.1424169.
    Abstract    



  148. WANG Y, Wang Y, Zhong W, Gulina K, et al
    Correlation between miR-19a inhibition and radiosensitivity in SiHa cervical cancer cells.
    J BUON. 2017;22:1505-1508.
    Abstract    

    Abstract available

  149. PAN Q, Liu R, Banu H, Ma L, et al
    Inhibition of isoprenylcysteine carboxylmethyltransferase sensitizes common chemotherapies in cervical cancer via Ras-dependent pathway.
    Biomed Pharmacother. 2018;99:169-175.
    Abstract    

    Abstract available

  150. CHAPMAN CH, Polan D, Vineberg K, Jolly S, et al
    Deformable image registration-based contour propagation yields clinically acceptable plans for MRI-based cervical cancer brachytherapy planning.
    Brachytherapy. 2018 Jan 10. pii: S1538-4721(17)30540.
    Abstract    

    Abstract available

  151. XU HH, Zheng LZ, Lin AF, Dong SS, et al
    Human papillomavirus (HPV) 18 genetic variants and cervical cancer risk in Taizhou area, China.
    Gene. 2018 Jan 10. pii: S0378-1119(18)30045-3. doi: 10.1016/j.gene.2018.
    Abstract    

    Abstract available

  152. SAETERDAL I, Juvet LK, Natvig Norderhaug I
    Update on current care guideline: Cytological changes in the cervix, vagina and vulva.
    Duodecim. 2017;133:183-5.
    Abstract    

    Abstract available

  153. TAO G, Yaling G, Zhan G, Pu L, et al
    Human papillomavirus genotype distribution among HPV-positive women in Sichuan province, Southwest China.
    Arch Virol. 2018;163:65-72.
    Abstract    

    Abstract available

  154. HAMEED A, Dekovich AA, Lum PJ, Shafi MA, et al
    Dysphagia: An Unusual Presentation of Metastatic Uterine Cervical Carcinoma.
    J Coll Physicians Surg Pak. 2017;27:187-188.
    Abstract    

    Abstract available

  155. SHEN-GUNTHER J, Wang Y, Lai Z, Poage GM, et al
    Deep sequencing of HPV E6/E7 genes reveals loss of genotypic diversity and gain of clonal dominance in high-grade intraepithelial lesions of the cervix.
    BMC Genomics. 2017;18:231.
    Abstract    

    Abstract available

  156. TRAN AQ, Sullivan SA, Gehrig PA, Soper JT, et al
    Robotic Radical Parametrectomy With Upper Vaginectomy and Pelvic Lymphadenectomy in Patients With Occult Cervical Carcinoma After Extrafascial Hysterectomy.
    J Minim Invasive Gynecol. 2017;24:757-763.
    Abstract    

    Abstract available

  157. PLATH J, Siebenhofer A, Kone I, Hechtner M, et al
    Frequency of a positive family history of colorectal cancer in general practice: a cross-sectional study.
    Fam Pract. 2017;34:30-35.
    Abstract    

    Abstract available

  158. HARTZEMA AG
    Comments on prenatal diethylstilbestrol exposure and high-grade squamous cell neoplasia of the lower genital tract.
    Am J Obstet Gynecol. 2017;216:197-198.
    Abstract    



  159. LEE SH, Cho KJ, Ko MH, Cho HY, et al
    Factors associated with parametrial involvement in patients with stage IB1 cervical cancer: Who is suitable for less radical surgery?
    Obstet Gynecol Sci. 2018;61:88-94.
    Abstract    

    Abstract available

  160. GUO KY, Han L, Li X, Yang AV, et al
    Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.
    Oncotarget. 2017;8:114123-114135.
    Abstract    

    Abstract available

  161. ZHANG X, Cha IH, Kim KY
    Highly preserved consensus gene modules in human papilloma virus 16 positive cervical cancer and head and neck cancers.
    Oncotarget. 2017;8:114031-114040.
    Abstract    

    Abstract available

  162. YAN D, Zhu D, Zhao X, Su J, et al
    SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer.
    Cancer Cell Int. 2018;18:8.
    Abstract    

    Abstract available

  163. MAPANGA W, Chipato T, Feresu SA
    Treatment of cervical cancer in HIV-seropositive women from developing countries: a protocol for a systematic review.
    Syst Rev. 2018;7:22.
    Abstract    

    Abstract available

  164. LIU G, Sharma M, Tan N, Barnabas R, et al
    HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis.
    AIDS. 2018 Jan 24. doi: 10.1097/QAD.0000000000001765.
    Abstract    

    Abstract available

  165. VU LTH, Tran HTD, Nguyen BT, Bui HTT, et al
    Community-Based Screening for Cervical Cancer Using Visual Inspection With Acetic Acid: Results and Lessons Learned From a Pilot Study in Vietnam.
    J Public Health Manag Pract. 2018;24 Suppl 2 Supplement.
    Abstract    

    Abstract available

  166. DONG P, Hao F, Dai S, Tian L, et al
    Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.
    J Recept Signal Transduct Res. 2018;38:83-88.
    Abstract    

    Abstract available

  167. KONG SY, Huang K, Zeng C, Ma X, et al
    The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis.
    Sci Rep. 2018;8:1545.
    Abstract    

    Abstract available

  168. BRODERSEN J
    High incidence of cervical cancer in women over 60 is likely due to less intensive cervical screening in this generation of women.
    Evid Based Med. 2018;23:37.
    Abstract    



  169. RAVIKUMAR KE, MacLaughlin KL, Scheitel MR, Kessler M, et al
    Improving the Accuracy of a Clinical Decision Support System for Cervical Cancer Screening and Surveillance.
    Appl Clin Inform. 2018;9:62-71.
    Abstract    

    Abstract available

  170. SHI X, Yang J, Wei G
    Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through the Akt/GSK3beta signaling pathway in human cervical cancer cells.
    Mol Med Rep. 2018 Jan 18. doi: 10.3892/mmr.2018.8454.
    Abstract    

    Abstract available

  171. WANG L, Zhao Y, Wu Q, Guan Y, et al
    Therapeutic effects of beta-elemene via attenuation of the Wnt/beta-catenin signaling pathway in cervical cancer cells.
    Mol Med Rep. 2018 Jan 18. doi: 10.3892/mmr.2018.8455.
    Abstract    

    Abstract available

  172. ABDULLAHI A, Mustapha MI, David DA, Ayodeji OT, et al
    Human immunodeficiency virus seroprevalence in patients with invasive cervical cancer in Zaria, North-Western Nigeria.
    Ann Afr Med. 2018;17:17-21.
    Abstract    

    Abstract available

  173. VIRANI S, Sriplung H, Bilheem S, Sripan P, et al
    Effect of the national screening program on malignancy status of cervical cancer in Northern Thailand.
    Int J Public Health. 2018 Jan 23. pii: 10.1007/s00038-018-1077.
    Abstract    

    Abstract available

  174. SHARMA A, Gorey B, Casey A
    In vitro comparative cytotoxicity study of aminated polystyrene, zinc oxide and silver nanoparticles on a cervical cancer cell line.
    Drug Chem Toxicol. 2018 Jan 23:1-15. doi: 10.1080/01480545.2018.1424181.
    Abstract    

    Abstract available

  175. TAMURA R, Yoshihara K, Saito T, Ishimura R, et al
    Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
    Oncogenesis. 2018;7:4.
    Abstract    

    Abstract available

  176. XU H, Yuan Y, Wu W, Zhou M, et al
    Hypoxia stimulates invasion and migration of human cervical cancer cell lines HeLa/SiHa through the Rab11 trafficking of integrin alphavbeta3/FAK/PI3K pathway-mediated Rac1 activation.
    J Biosci. 2017;42:491-499.
    Abstract    

    Abstract available

  177. HE L, Yang H, Zhou S, Zhu H, et al
    Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells.
    DNA Repair (Amst). 2018;63:1-9.
    Abstract    

    Abstract available

  178. ALIFU M, Fan P, Kuerban G, Yao X, et al
    Frequency distribution of HLA alleles and haplotypes in Uyghur women with advanced squamous cell cervical cancer and relation to HPV status and clinical outcome.
    Arch Gynecol Obstet. 2018 Jan 22. pii: 10.1007/s00404-018-4662.
    Abstract    

    Abstract available

  179. KARIM S, Souho T, Benlemlih M, Bennani B, et al
    Cervical Cancer Induction Enhancement Potential of Chlamydia Trachomatis: A Systematic Review.
    Curr Microbiol. 2018 Jan 22. pii: 10.1007/s00284-018-1439.
    Abstract    

    Abstract available

  180. CLARKE MA, Fetterman B, Cheung LC, Wentzensen N, et al
    Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
    J Clin Oncol. 2018 Jan 22:JCO2017753442. doi: 10.1200/JCO.2017.75.3442.
    Abstract    

    Abstract available

  181. SHU T, Zhao D, Li B, Wang Y, et al
    Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer: 10 years' experience of National Cancer Center in China.
    Chin J Cancer Res. 2017;29:510-520.
    Abstract    

    Abstract available

  182. XIA C, Ding C, Zheng R, Zhang S, et al
    Trends in geographical disparities for cervical cancer mortality in China from 1973 to 2013: a subnational spatio-temporal study.
    Chin J Cancer Res. 2017;29:487-495.
    Abstract    

    Abstract available

  183. LI X, Zheng R, Li X, Shan H, et al
    Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014.
    Chin J Cancer Res. 2017;29:477-486.
    Abstract    

    Abstract available

  184. SONG B, Ding C, Chen W, Sun H, et al
    Incidence and mortality of cervical cancer in China, 2013.
    Chin J Cancer Res. 2017;29:471-476.
    Abstract    

    Abstract available

  185. KIM K, Xue QL, Walton-Moss B, Nolan MT, et al
    Decisional balance and self-efficacy mediate the association among provider advice, health literacy and cervical cancer screening.
    Eur J Oncol Nurs. 2018;32:55-62.
    Abstract    

    Abstract available

  186. CHAI W, Xu Y, Zhang W, Wei Z, et al
    Irreversible electroporation in the eradication of rabbit VX2 cervical tumors.
    Biomed Microdevices. 2017;19:90.
    Abstract    

    Abstract available

  187. ANTONIALI G, Serra F, Lirussi L, Tanaka M, et al
    Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism.
    Nat Commun. 2017;8:797.
    Abstract    

    Abstract available

  188. SANFRANCESCO J, Williamson SR, Kum JB, Zhang S, et al
    Mullerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations.
    Clin Genitourin Cancer. 2017;15:e1007-e1014.
    Abstract    

    Abstract available

  189. WEI L, Chen J, Zhao S, Ding J, et al
    Thermo-sensitive polypeptide hydrogel for locally sequential delivery of two-pronged antitumor drugs.
    Acta Biomater. 2017;58:44-53.
    Abstract    

    Abstract available

  190. YU SC, Huang HH, Li CC, Tang JL, et al
    Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase.
    Biol Blood Marrow Transplant. 2017;23:1367-1373.
    Abstract    

    Abstract available

  191. KUMVONGPIN R, Jearanaikoon P, Wilailuckana C, Sae-Ung N, et al
    Detection assay for HPV16 and HPV18 by loopmediated isothermal amplification with lateral flow dipstick tests.
    Mol Med Rep. 2017;15:3203-3209.
    Abstract    

    Abstract available

  192. MAUFFREY C, Giannoudis P, Civil I, Gray AC, et al
    Pearls and pitfalls of open access: The immortal life of Henrietta Lacks.
    Injury. 2017;48:1-2.
    Abstract    



  193. KATZ ML PHD, Zimmermann BJ Ba, Moore D Rma, Paskett ED PhD, et al
    Perspectives from health-care providers and women about completing human papillomavirus (HPV) self-testing at home.
    Women Health. 2017;57:1161-1177.
    Abstract    

    Abstract available

  194. SHAIN AF, Kwok S, Folkins AK, Kong CS, et al
    Utility of p16 Immunohistochemistry in Evaluating Negative Cervical Biopsies Following High-risk Pap Test Results.
    Am J Surg Pathol. 2018;42:69-75.
    Abstract    

    Abstract available

  195. RAZZAGHI H, Saraiya M, Thompson TD, Henley SJ, et al
    Five-year relative survival for human papillomavirus-associated cancer sites.
    Cancer. 2018;124:203-211.
    Abstract    

    Abstract available

  196. CHOI YW, Kang MC, Seo YB, Namkoong H, et al
    Intravaginal administration of Fc-fused IL-7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0423.2016.
    Abstract    

    Abstract available

  197. PEDERSEN K, Burger EA, Nygard M, Kristiansen IS, et al
    Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Eur J Cancer. 2018;91:68-75.
    Abstract    

    Abstract available

  198. XIANG L, Jiang W, Ye S, He T, et al
    ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Gynecol Oncol. 2017 Dec 23. pii: S0090-8258(17)31614.
    Abstract    

    Abstract available

  199. LEE J, Lin JB, Chang CL, Sun FJ, et al
    Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
    Gynecol Oncol. 2017 Dec 18. pii: S0090-8258(17)31550.
    Abstract    

    Abstract available

  200. BACORRO W, Dumas I, Escande A, Gouy S, et al
    Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
    Gynecol Oncol. 2018 Jan 8. pii: S0090-8258(17)31621.
    Abstract    

    Abstract available

  201. PARK SH, Cheon H, Chong GO, Jeong SY, et al
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(18)30037.
    Abstract    

    Abstract available

  202. DOSTALEK L, Zikan M, Fischerova D, Kocian R, et al
    SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
    Gynecol Oncol. 2018 Jan 21. pii: S0090-8258(18)30001.
    Abstract    

    Abstract available

  203. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
    Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
    Int J Cancer. 2017;140:247-248.
    Abstract    



  204. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
    Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
    Abstract    

    Abstract available

  205. CHONG GO, Lee YH, Lee HJ, Hong DG, et al
    Comparison of the Long-Term Oncological Outcomes Between the Initial Learning Period of Robotic and the Experienced Period of Laparoscopic Radical Hysterectomy for Early-Stage Cervical Cancer.
    Int J Gynecol Cancer. 2018 Jan 4. doi: 10.1097/IGC.0000000000001172.
    Abstract    

    Abstract available

  206. GUO X, Dong Z, Yamada S, Li Y, et al
    Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma.
    Int J Gynecol Cancer. 2017;27:206-213.
    Abstract    

    Abstract available

  207. HARTMAN CA, Teixeira JC, Barbosa SB, Figueiredo SM, et al
    Analysis of Conservative Surgical Treatment and Prognosis of Microinvasive Squamous Cell Carcinoma of the Cervix Stage IA1: Results of Follow-Up to 20 Years.
    Int J Gynecol Cancer. 2017;27:357-363.
    Abstract    

    Abstract available

  208. O'DONNELL B, Shiao JC, Pezzi TA, Waheed N, et al
    Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
    Int J Gynecol Cancer. 2018 Jan 10. doi: 10.1097/IGC.0000000000001200.
    Abstract    

    Abstract available

  209. DEVOR EJ, Reyes HD, Gonzalez-Bosquet J, Warrier A, et al
    Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology.
    Int J Gynecol Cancer. 2017;27:784-790.
    Abstract    

    Abstract available

  210. SLAMA J, Fischerova D, Zikan M, Kocian R, et al
    Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers.
    Int J Gynecol Cancer. 2017;27:147-153.
    Abstract    

    Abstract available

  211. CIMA S, Perrone AM, Castellucci P, Macchia G, et al
    Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
    Int J Gynecol Cancer. 2018 Jan 24. doi: 10.1097/IGC.0000000000001207.
    Abstract    

    Abstract available

  212. MAHANTSHETTY U, Krishnatry R, Hande V, Jamema S, et al
    Magnetic Resonance Image Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: An Experience From a Tertiary Cancer Center in a Low and Middle Income Countries Setting.
    Int J Radiat Oncol Biol Phys. 2017;99:608-617.
    Abstract    

    Abstract available

  213. GLASER S, Mahantshetty U, Lee L, Klopp A, et al
    Genomics and 3-Dimensional Brachytherapy for Cervical Cancer: Significant Steps Forward.
    Int J Radiat Oncol Biol Phys. 2017;99:505-509.
    Abstract    



  214. DOUTRE S, Omar T, Goumbri-Lompo O, Kelly H, et al
    Cervical intraepithelial neoplasia (CIN) in African women living with HIV: role and effect of rigorous histopathological review by a panel of pathologists in the HARP study endpoint determination.
    J Clin Pathol. 2018;71:40-45.
    Abstract    

    Abstract available

  215. LEINONEN MK, Schee K, Jonassen CM, Lie AK, et al
    Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.
    J Clin Virol. 2017;99-100:22-30.
    Abstract    

    Abstract available

  216. GHOSH I, Muwonge R, Mittal S, Banerjee D, et al
    Association between high risk human papillomavirus infection and co-infection with Candida spp. and Trichomonas vaginalis in women with cervical premalignant and malignant lesions.
    J Clin Virol. 2017;87:43-48.
    Abstract    

    Abstract available

  217. SILVERBERG MJ, Leyden WA, Chi A, Gregorich S, et al
    Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia.
    Obstet Gynecol. 2018;131:47-55.
    Abstract    

    Abstract available

  218. SHI X, Ran L, Liu Y, Zhong SH, et al
    Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
    Oncol Rep. 2018 Jan 5. doi: 10.3892/or.2018.6195.
    Abstract    

    Abstract available

  219. LI C, Zheng X, Li W, Bai F, et al
    Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms.
    BMC Cancer. 2018;18:61.
    Abstract    

    Abstract available


  220. Correction: Effect of cervical cancer education and provider recommendation for screening on screening rates: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0190661.
    Abstract    

    Abstract available

  221. ANDERSSON S, Belkic K, Demirbuker SS, Mints M, et al
    Perceived cervical cancer risk among women treated for high-grade cervical intraepithelial neoplasia: The importance of specific knowledge.
    PLoS One. 2017;12:e0190156.
    Abstract    

    Abstract available

  222. DA SILVA ERP, de Souza AS, de Souza TGB, Tsuha DH, et al
    Screening for cervical cancer in imprisoned women in Brazil.
    PLoS One. 2017;12:e0187873.
    Abstract    

    Abstract available

  223. BADANO I, Sanabria DJ, Totaro ME, Rubinstein S, et al
    Mitochondrial DNA ancestry, HPV infection and the risk of cervical cancer in a multiethnic population of northeastern Argentina.
    PLoS One. 2018;13:e0190966.
    Abstract    

    Abstract available

  224. TEAME H, Addissie A, Ayele W, Hirpa S, et al
    Factors associated with cervical precancerous lesions among women screened for cervical cancer in Addis Ababa, Ethiopia: A case control study.
    PLoS One. 2018;13:e0191506.
    Abstract    

    Abstract available

  225. ZENG Q, Zhao RX, Chen J, Li Y, et al
    O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis.
    Proc Natl Acad Sci U S A. 2016 Aug 1. pii: 201606801.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;